Availability and Utilization of Clinical Genomic Sequencing globally
  • Phillips KA, Douglas MP, Marshall DA. Use of Clinical Genomic Sequencing Expands but More Data on Implementation Are Needed. JAMA. 2020;324(20):2029-2030.

  • Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and Funding of Clinical Genomic Sequencing Globally. BMJ Global Health. 2021;6:e004415.

Theme Section - Methods for Moving Evaluation of Precision Medicine into Practice and Policy - Value in Health
  • Phillips KA. Introduction to Themed Papers: Methods for Moving Evaluation of Precision Medicine into Practice and Policy. Value Health. 2020;23(5):527-528.

  • Deverka PA, Douglas MP, Phillips KA. Use of Real World Evidence in U.S. Payer Coverage Decision-making for NGS-based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020;23(5):540-550.

  • Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips KA, Ijzerman M. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value Health. 2020;23(5):566-573.

  • Mackay Z, Dukhovny D, Parad RB, Phillips KA, Beggs AH, Green R, Christensen KA. Methods for Identifying Health Care Attributable to Unexpected Genomic Results. Value Health. 2020;23(5):559-565.

  • Trosman JR, Douglas MP, Liang S, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights from a Temporal Assessment of Increases in U.S. Private Payer Coverage of Tumor Sequencing from 2015 to 2019. Value Health. 2020;23(5):551-558.

Theme Section - Assessing the Value of Next Generation Sequencing - Value in Health
  • Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042.

  • Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using ‘big’ data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053.

  • Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of Health and Non-health Benefits from Next Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047.

  • Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. 2018; 21(9):1054-1061.

  • Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062- 1068.

Theme Issue - Precision Medicine - Health Affairs
  • Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Affairs. 2018;37(5): 694-701.

  • Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Affairs. 2018;37(5): 710-716.

Theme Section - Value to Decision Makers of Evaluations of Personalized / Precision Medicine: Applications to Other Emerging Technologies - Value in Health
  • Phillips KA. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017;20(1):30-31.

  • Phillips KA, Douglas MP, Trosman JR, Marshall DA. “What goes around comes around”: lessons learned from economic evaluations of personalized medicine applied to digital medicine. Value Health. 2017;20(1):32- 38.

  • Marshall DA, Gonzalez JM, MacDonald KV, Johnson FR. Estimating preferences for complex health technologies: lessons learned and implications for personalized medicine. Value Health. 2017;20(1):17-24.

  • Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision making on medical innovations in a changing health care environment: insights from accountable care organizations and payers on personalized medicine and other technologies. Value Health. 2017;20(1):25-31.

  • Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT. Lessons learned when introducing pharmacogenomic panel testing into clinical practice. Value Health. 2017;20(1):39-44.